Table of Contents UNITED STATES SECURITIES AND...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE...
As filed with the Securities and Exchange Commission on March 14, 2019 Registration No. 333- &n...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form...
BOSTON, March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on...
BOSTON, March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...
BOSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...
BOSTON, March 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) a clinical-stage biopharmaceutical...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.